معرفی
Rakesh Naidu is a Professor in Biomedical Science at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia. He previously served as a lecturer at International Medical University and the Department of Molecular Medicine, Faculty of Medicine, University of Malaya. His academic and research career spans molecular oncology, cancer therapeutics, and cancer venomics, with a strong focus on translational research.
- PhD in Molecular Oncology, Universiti Malaya
- MSc in Molecular Oncology, Universiti Malaya
- BSc(Ed) in Science Education, Universiti Sains Malaysia
Dr. Naidu’s research centers on understanding molecular alterations in cancers such as breast, prostate, colon, lung, and glioblastoma. His group investigates synthetic curcumin analogues (diarylpentanoids) and natural venom components for anticancer activity using genomics, transcriptomics, and proteomics. High-throughput techniques like mass spectrometry and microarrays help identify therapeutic targets and pathways. His work contributes to the development of novel anticancer drugs and diagnostics, aligning with UN Sustainable Development Goals in health and well-being.
His recent publications (2021–2025) emphasize cancer mechanisms, proteomics, venom-based therapeutics, and neuroprotection. The articles reflect a consistent trend in molecular oncology, with increasing focus on omics technologies, drug development, and interdisciplinary approaches combining pharmacology, toxicology, and neuroscience.
- Best e-poster presentation entitled Enhancing Medical Students’ Understanding of Basic Immunology through Innovative Approaches (2024)
- MOST INSPIRING SUPERVISOR (2022)
- OUTSTANDING SUPERVISION AND EDUCATIONAL EXCELLENCE (2023)
- Supervisor of the Year 2024
Dr. Naidu has successfully secured multiple internal and external research grants in molecular oncology and cancer therapeutics. He has supervised numerous PhD and Master’s students and is currently accepting new PhD candidates with backgrounds in biomedical sciences, biochemistry, or molecular biology. His supervisory roles extend to non-HDR projects and mentorship programs. He is actively involved in organizing and speaking at scientific conferences, including the Brain Tumour Conference 2024 and the 35th Pezcoller Symposium.
His research team collaborates on projects such as developing universal antivenom, creating receptor-targeted fluorescent probes for breast cancer imaging, and studying EV-D68 neuropathogenesis. These efforts are supported by advanced omics platforms and interdisciplinary partnerships across Malaysia and internationally.
